Tests CB-011 cell therapy in adults with relapsed or refractory multiple myeloma
Tests CB-011, a modified donor cell therapy, in adults with returning multiple myeloma.
Key facts
- Who runs it
- Caribou Biosciences, Inc.
- Where
- Aurora, Birmingham, Charlotte, Cincinnati, Cleveland, Dallas, Durham, Hackensack, Lexington, Miami, Milwaukee, Nashville, New York, Richmond, and Salt Lake City, United StatesSee the 16 sites
- Trial code
- Registry title
- CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 50 people, planned
- Started
- 6 Feb 2023
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- CB-011
- Record updated
- 25 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose multiple myeloma has come back or stopped responding to treatment, and who have already had at least 3 earlier lines of treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that has come back or no longer responds to treatment (relapsed/refractory), with disease that can be measured.
- Earlier treatment
- At least 3 earlier lines of myeloma treatment, including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody. No earlier CAR-T cell therapy of any kind.
Main reasons for not taking part
- Earlier CAR-T cell therapy directed at any target
- Autologous stem cell transplant within 6 weeks, or allogeneic stem cell transplant within 6 months, before lymphodepletion
- Known active or past involvement of the central nervous system (CNS)
- Stroke or seizure within 6 months of signing the consent form
- HIV, hepatitis B or hepatitis C infection
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.)
- Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody as part of a prior line of therapy, either in monotherapy or in combination
- Eastern Cooperative Oncology Group performance status grade of 0 or 1
- Adequate hematologic, renal, hepatic, pulmonary, and cardiac function
Who cannot take part
- Prior treatment with CAR-T cell therapy directed at any target
- Autologous stem cell transplant within the last 6 weeks before lymphodepletion
- Allogeneic stem cell transplant within 6 months before lymphodepletion
- Known active or prior history of CNS involvement
- Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion
- Stroke or seizure within 6 months of signing ICF
- Seropositive for or history of human immunodeficiency virus
- Hepatitis B infection
- Hepatitis C infection
- Known life-threatening allergies, hypersensitivity, or intolerance to CB-011 or its excipients
Where in United States
- CU Anschutz Medical Campus, Anshutz Cancer PavillionAurora, United StatesContact: Rona WangTaking people
- University of Alabama at BirminghamBirmingham, United StatesContact: Luciano Costa, MDTaking people
- Levine Cancer InstituteCharlotte, United StatesContact: Kelly BumgarnerTaking people
- Oncology Hematology Care, IncCincinnati, United StatesContact: Doug HartTaking people
- Cleveland ClinicCleveland, United StatesContact: Faiz Anwer, MD (principal investigator)Taking people
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Marcella AguilarTaking people
- Duke University Health System (DUHS)Durham, United StatesContact: Matthew FisherTaking people
- Hackensack Meridian John Theurer Cancer CenterHackensack, United StatesContact: Oncology Clinical Research Referral OfficeTaking people
- University of Kentucky/Markey Cancer CenterLexington, United StatesContact: Ashley Walton-RobbinsTaking people
- Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics)Miami, United StatesContact: Jay Spiegel, MDTaking people
- Froedtert and the Medical College of WisconsinMilwaukee, United StatesContact: Danielle KingTaking people
- Tennessee OncologyNashville, United StatesContact: Jesus Berdeja, MDTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Adriana Rossi, MDTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Sham Mailankody, MBBSTaking people
- Virginia Commonwealth UniversityRichmond, United StatesContact: Johanna BiamonteTaking people
- Huntsman Cancer Institute/University of UtahSalt Lake City, United StatesContact: Collind BoyingtonTaking people
About the trial
What the trial wants to find out
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
The group in the trial
- CB-011Treatment being tested
* Part A Escalation with CB-011 in ascending doses using a traditional 3+3 design. * Part B Expansion. Up to 30 participants will be enrolled to receive CB-011 at the RDE/MTD and/or RP2D determined in Plan A
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
- Plain-language title
- Tests CB-011 cell therapy in adults with relapsed or refractory multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 September 2025